FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Instruction 1(b).	Check this box if no longer subje to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
-------------------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name ar Subran	2. Issuer Name and Ticker or Trading Symbol <u>Ventyx Biosciences, Inc.</u> [VTYX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner								
(Last)	 3. Date of Earliest Transaction (Month/Day/Year) 06/14/2023 4. If Amendment, Date of Original Filed (Month/Day/Year) 								cer (give ti			er (specify				
C/O VENTYX BIOSCIENCES, INC. ENCINITAS BLVD, SUITE 250								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person								
(Street) ENCINITAS CA 92(2024									n filed by				
(City)	(St		(ip)	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
1. Title of Security (Instr. 3) (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and		ired (A) or	5. Amount of		6. Ownership Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	Amount	(A) or (D)	Price	Reporte Transac	Reported Transaction(s) (Instr. 3 and 4)		4)			
Common Stock 06/14/2023						S		50,000	D	\$35.0757	(1) 9,787,045			I	See Footnotes ⁽ 3)(4)(5)(6)	
		Tab	le II - Derivativ (e.g., put							r Beneficia e securitie		ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	rcise (Month/Day/Year) if any Code (Instr. of of tive ty by Code (Instr. of (Month/Day/Year) 8) Se Act (A Di of (Intri- Act (A Di Of (Intri- Act (A) Di Act (A) Di (A) Di Act (A) Di (A)		5. Number of Derivati Securiti Acquire (A) or Dispose of (D) (Instr. 3	(Month/Day/Year rivative curities quired or sposed (D) str. 3, 4				7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	derivati Securiti Benefic Owned Followin Reporte Transac	9. Number of derivative Securities Beneficially Owned Following Following Reported Transaction(s) (Instr. 4)		Benefic Owners ct (Instr. 4		

Explanation of Responses:

1. Represents the weighted average share price of an aggregate total of 50,000 shares sold in the price range of \$35.00 to \$35.5081. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

(A) (D) Date

Exercisable

2. Consists of: (i) 5,286,971 shares held by NSV Investments I, LP, (ii) 1,037,831 shares held by NSV Investments III, LP, (iii) 374,756 shares held by NSV Master Limited Partnership II, LP, (iv) 320,831 shares held by NSV 2019 Opportunities Fund, LP, (v) 273,782 shares held by NSV 2018 New Horizons Fund, LP, (vi) 330,816 shares held by Life & Tech, (vii) 434,423 shares held by NSV SV Partners III, LP, (ix) 279,748 shares held by NSV Investments II, LP, (x) 296,359 shares held by NSV Partners II, LLC, (xi) 53,466 shares held by NSV Growth Opportunities Fund, LP, (xii) 38,240 shares held by New Science Ventures Fund III, LP, (xiii) 33,610 shares held by NSV 2017 Opportunities Fund, LP, (xi) 23,436 shares held by NSV 2018 Opportunities Fund, LP, (xv) 18,126 shares held by NSV 2016 Opportunities Fund, LP,

3. (Continued from Footnote 2): (xvi) 12,056 shares held by New Science Ventures Fund III (Offshore), LP, and (xvii) 4,985 shares held by NSV 2016 Opportunities Fund (Offshore), LP (collectively, the "NSV Funds"). The NSV Funds disclaim beneficial ownership over the shares owned by them, except to the extent of their pecuniary interest therein

4. NSV Partners III, LP is the general partner of NSV 2018 New Horizons Fund, LP, NSV Investments I, LP, NSV 2018 Opportunities Fund, LP, NSV 2019 Opportunities Fund, LP, NSV Growth Opportunities Fund, LP, NSV Investments III, LP, and NSV Investments II, LP.

5. NSV Partners II, LLC is the general partner of New Science Ventures Fund III, LP, New Science Ventures Fund III (Offshore), LP, NSV 2016 Opportunities Fund, LP, NSV 2016 Opportunities Fund, (Offshore), LP, NSV 2017 Opportunities Fund, LP, and NSV Master Limited Partnership II, LP.

6. The Reporting Person is the majority member and managing member of NSV Partners III GP, LLC, and may be deemed to have voting and dispositive power over the shares owned by each entity of which NSV Partners III, LP is general partner. The Reporting Person is the majority member and managing member NSV Partners II, LLC, and may be deemed to have voting and dispositive power over the shares owned by each entity of which NSV Partners II, LLC is general partner. The Reporting Person is the majority member and managing member of NSV Management, LLC, and may be deemed to share voting and dispositive power over the shares held by Life & Tech, for which NSV Management, LLC is the investment advisor. The Reporting Person disclaims beneficial ownership over the shares owned by each of the NSV Funds, except to the extent of his pecuniary interest therein.

Remarks:

/s/ Christopher Krueger, as <u>Attorney-in-Fact</u>

Amount Number

Shares

of

Title

Expiration

Date

06/16/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden 0.5 hours per response